Jan Wald
Jan Wald
bid learned sensitive
It's still a possibility. But the valuation is high, and one thing we learned from the J&J bid for Guidant is they are very sensitive to valuation.
boston company fda gain permit product quality saying scientific seemed until
What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.
boston deal power reach scientific
Boston Scientific will do everything in its power to reach a deal with Guidant.
buying company easy faces growth half impact johnson problem size
The problem that Johnson & Johnson and any company even half the size of Johnson & Johnson faces is buying something that can impact their growth rate, and that's not an easy task.
chance good sure
I don't think it's a sure thing by any stretch, but I think they have a good chance of making it.
along believe boston deal matter small strategic
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
time
But that is an awfully long time to look out for pharmaceuticals.
acquire growth investors rate
My sense is J&J is going to have to acquire to get a growth rate that investors will think is respectable.
company education loses market money training
One thing the company loses by not being part of J&J is not having more money for market development education and training
feeling
I have a feeling that Temecula is pretty safe.
less serious
It's less serious than I thought it was.
bid learnt sensitive
It's still a possibility. But the valuation is high, and one thing we learnt from the J&J bid for Guidant is they are very sensitive to valuation.
bent
It underscores why they were so bent on doing the Guidant deal.
They were being nickel-and-dimed by J&J. They had to get out of that loop.